AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Amazon Explores AI Content Marketplace With Media Publishers 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
NEW YORK, Jan. 09, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Alkermes plc ("Alkermes") (NASDAQ:ALKS) securities between February 24, 2015 and November 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/alkermes-plc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Alkermes had engaged in deceptive marketing campaigns to influence policymakers to use Vivitrol in addiction treatment programs over more scientifically proven and efficacious alternatives; (ii) the foregoing conduct, when disclosed, would subject Alkermes to heightened regulatory and legislative scrutiny; (iii) accordingly, the Company's revenues derived from Vivitrol during the Class Period were unsustainable; and (iv) as a result of the foregoing, Alkermes shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.
If you suffered a loss in Alkermes you have until January 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/alkermes-plc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
